ArticleMetabolic brain disease2026
Diosgenin ameliorates behavioral alterations, hippocampal oxidative stress markers, and apoptotic deficits in a rat model of autism induced by valproic acid.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimAutism Spectrum Disorder (ASD) is characterized by difficulties in social communication, anxiety, and repetitive behaviors, and it may also be associated with cognitive memory impairment. The etiology of ASD is complex, and current treatments have limited efficacy in addressing all ASD-related symptoms. Diosgenin (Dios) has shown neuroprotective effects in various neurological conditions. This study aimed to investigate the effects of Dios on hippocampal oxidative stress, apoptosis, and behavioral outcomes in a Valproic acid (VPA) induced rat model of Autism.
methodsWe examined the potential role of Dios in altering recognition memory behaviors in male rats prenatally exposed toVPA (600 mg/kg). The offspring received Dios (40 mg/kg) or Carboxymethyl cellulose (5 mg/kg) from postnatal day (PND) 23 to PND 52. Subsequently, these animals were tested with behavioral tests, including the Three-Chamber, Marble Burying, Open Field, and Passive Avoidance tests (n=8). Additionally, reactive oxygen species (ROS) markers (GSH, CAT, ROS, n=3), apoptotic markers (Caspase3, Bax, Bcl-2, n=3), and histological evaluations (Nissl staining) were performed.
resultsVPA-exposed rats displayed Autism-like behavioral impairments, including deficits in recognition memory and increased repetitive/anxiety-like behaviors. Additionally, Caspase-3 and Bax were upregulated, and Bcl2 was downregulated in hippocampal tissues. The rats in the study displayed a reduced antioxidant function, as shown by the decreased levels of GSH and CAT. Treatment with Dios mitigated markers of apoptosis and ROS, and enhanced recognition memory behavior in rats exposed to VPA. Furthermore, those treated with Dios exhibited a decrease in dark cell rates in the CA1 region of the hippocampus.
conclusionThis study demonstrated that markers of apoptosis and oxidative stress are elevated in rats exposed to VPA. The administration of Dios significantly reduces these markers, which in turn alleviates neuronal damage in the hippocampus and behavioral symptoms. Overall, these findings provide preclinical evidence supporting the potential neuroprotective role of Dios in an experimental model of ASD.
Indexed as
Identifiers
42262415What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.